Ipilimumab/nivolumabImmune-mediated colitis : case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1885卷 / 1期

关键词：

D O I：

10.1007/s40278-021-07040-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：281 / 281

相关论文

共 50 条

[41] Ipilimumab/nivolumabImmune mediated type I diabetes: case report
Reactions Weekly, 2018, 1728 (1) : 198 - 198
[42] NivolumabImmune-mediated gastroduodenitis with ulceration leading to unremitting nausea and vomiting: case report
Reactions Weekly, 2017, 1673 (1) : 278 - 278
[43] Ipilimumab/NivolumabImmune hepatitis: case report
Reactions Weekly, 2024, 2037 (1) : 219 - 219
[44] NivolumabImmune-mediated liver toxicity and end-stage liver disease: case report
Reactions Weekly, 2021, 1836 (1) : 595 - 595
[45] Ipilimumab/NivolumabImmune checkpoint inhibitor-related diarrhoea and colitis: case report
Reactions Weekly, 2020, 1818 (1) : 153 - 153
[46] NivolumabImmune colitis: case report
Reactions Weekly, 2019, 1768 (1) : 251 - 251
[47] Crizotinib/ipilimumab/nivolumabImmune mediated hepatitis and lack of efficacy: case report
Reactions Weekly, 2022, 1903 (1) : 142 - 142
[48] Ipilimumab/nivolumabImmune related toxicities: case report
Reactions Weekly, 2022, 1901 (1) : 280 - 280
[49] Ipilimumab/nivolumabImmune related myositis: case report
Reactions Weekly, 2020, 1827 (1) : 185 - 185
[50] Ipilimumab/nivolumabImmune myocarditis: case report.
Reactions Weekly, 2020, 1802 (1) : 171 - 171

← 1 2 3 4 5 →